Search

Presents a transcript of the roundtable discussion on the changing role of beta blockers as first line therapy in the management of open-angle glaucoma at the 1997 meeting of the Association for Research in Vision and Ophthalmology. Improvements on nonselective beta blockers; Safeness of the drug, Betoptic S (beatxolol); Dosing schedules of beta blockers; Characteristics of an ideal beta blocker.

Discusses the usefulness of Ocugene glaucoma genetic test in determining the likelihood of glaucoma development or progression in certain patients. Qualifications of patients needed for the test; Factors that influence the need for a glaucoma genetic test; Views of several U.S. ophthalmologists on the importance of such testing.

Reports on the United States government approval of unoprostone isopropyl ophthalmic solution 0.15% from CIBA Vision for the treatment of open-angle glaucoma or ocular hypertension. Effects of the drug on intraocular pressure; Potential neuroprotective effects of the compound; Comparison to other anti-glaucoma drugs.